Literature DB >> 24343458

Therapy for Parkinson's disease: what is in the pipeline?

Fabrizio Stocchi1.   

Abstract

Despite advances in the treatment of Parkinson's disease there are still many unmet needs, including neuroprotection, treatment of motor complications, treatment of dyskinesia, treatment of psychosis, and treatment of nondopaminergic symptoms. In this review, I highlight the obstacles to develop a neuroprotective drug and some of the treatment strategies recently approved or still in clinical trials designed to meet these unmet needs.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24343458      PMCID： PMC3899489          DOI： 10.1007/s13311-013-0242-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


  69 in total

1.  Modeling Parkinson's disease.

Authors:  C Warren Olanow; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

Review 2.  Milestones in PD genetics.

Authors:  Thomas Gasser; John Hardy; Yoshikuni Mizuno
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

3.  Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Authors:  Robert A Hauser; Aaron L Ellenbogen; Leo Verhagen Metman; Ann Hsu; Martin J O'Connell; Nishit B Modi; Hsuan-Ming Yao; Sherron H Kell; Suneel K Gupta
Journal:  Mov Disord       Date:  2011-07-13       Impact factor: 10.338

Review 4.  Future treatments for Parkinson's disease: surfing the PD pipeline.

Authors:  Robert A Hauser
Journal:  Int J Neurosci       Date:  2011       Impact factor: 2.292

Review 5.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

6.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Authors:  Fabrizio Stocchi; Olivier Rascol; Karl Kieburtz; Werner Poewe; Joseph Jankovic; Eduardo Tolosa; Paulo Barone; Anthony E Lang; C Warren Olanow
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

7.  Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.

Authors:  Cristina Sampaio; Juliana Bronzova; Robert A Hauser; Anthony E Lang; Olivier Rascol; Serge V van de Witte; And Ad Theeuwes
Journal:  Mov Disord       Date:  2011-05-03       Impact factor: 10.338

Review 8.  The Parkinson Progression Marker Initiative (PPMI).

Authors: 
Journal:  Prog Neurobiol       Date:  2011-09-14       Impact factor: 10.885

9.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

10.  The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.

Authors:  Michael John Jackson; Terrance H Andree; Matthew Hansard; Diane C Hoffman; Mark R Hurtt; John H Kehne; Thomas A Pitler; Lance A Smith; Gary Stack; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2009-10-07       Impact factor: 3.575
View more
  7 in total

1.  Editorial: Neurotherapeutics of movement disorders.

Authors:  Stewart A Factor; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.

Authors:  Athanasios D Spathis; Xenophon Asvos; Despina Ziavra; Theodoros Karampelas; Stavros Topouzis; Zoe Cournia; Xiaobing Qing; Pavlos Alexakos; Lisa M Smits; Christina Dalla; Hardy J Rideout; Jens Christian Schwamborn; Constantin Tamvakopoulos; Demosthenes Fokas; Demetrios K Vassilatis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-27       Impact factor: 11.205

3.  Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase.

Authors:  Annah N Mpitimpiti; Jacobus P Petzer; Anél Petzer; Johannes H L Jordaan; Anna C U Lourens
Journal:  Mol Divers       Date:  2019-01-21       Impact factor: 2.943

4.  A metabolic biomarker predicts Parkinson's disease at the early stages in patients and animal models.

Authors:  David Mallet; Thibault Dufourd; Mélina Decourt; Carole Carcenac; Paola Bossù; Laure Verlin; Pierre-Olivier Fernagut; Marianne Benoit-Marand; Gianfranco Spalletta; Emmanuel L Barbier; Sebastien Carnicella; Véronique Sgambato; Florence Fauvelle; Sabrina Boulet
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808

Review 5.  Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons.

Authors:  Mahdi Eskandarian Boroujeni; Mossa Gardaneh
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

6.  Outlining a Population "at Risk" of Parkinson's Disease: Evidence from a Case-Control Study.

Authors:  Tommaso Schirinzi; Giuseppina Martella; Alessio D'Elia; Giulia Di Lazzaro; Paola Imbriani; Graziella Madeo; Leonardo Monaco; Marta Maltese; Antonio Pisani
Journal:  Parkinsons Dis       Date:  2016-08-29

7.  Contribution of syndecans to cellular uptake and fibrillation of α-synuclein and tau.

Authors:  Anett Hudák; Erzsébet Kusz; Ildikó Domonkos; Katalin Jósvay; Alpha Tom Kodamullil; László Szilák; Martin Hofmann-Apitius; Tamás Letoha
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.